YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.16 (market cap $28.69M), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.72 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 2047.4× YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF for 61 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| QDTY | TAK | |
|---|---|---|
Market Cap | $28.69M | $58.74B |
Volume | 22,490 | 3,110,994 |
Sector | Income / Options Overlay | Health |
52-Week High | $46.71 | $19.05 |
52-Week Low | $36.57 | $13.23 |
Typical Hold Time | 61 Days | 1 Days |
Enterprise Value | — | $86.65B |
Dividend Yield | — | 3.33% |
Trailing returns across standard periods
Latest headlines on both assets
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →